

IN THE CLAIMS:

Please amend the claims as follows:

Claims 1-40 (Canceled)

Claims 41 and 42 (Canceled)

RECEIVED

OCT 29 2003

TECH CENTER 1600/2900

43. (Currently amended) ~~The method of claim 41, further comprising~~ A method for administering a recombinant adenovirus containing a gene of interest to a human subject believed to be in need of said method, said method comprising:

providing a human subject with an adenovirus lacking said gene of interest;

raising a neutralizing humoral response in the human subject to said adenovirus lacking the gene of interest;

providing the human subject with a second dose of said adenovirus lacking the gene of interest prior to said administering said recombinant adenovirus containing the gene of interest; and

administering a recombinant adenovirus containing the gene of interest, wherein said neutralizing humoral response is cross-reactive against said recombinant adenovirus containing the gene of interest.

44. (Currently amended) The method according to claim 44 ~~43~~, wherein said gene of interest is interleukin.

45. (Previously presented) The method according to claim 44, wherein said gene of interest is interleukin-3.

Application No. 09/733,865
Amdt. dated October 24, 2003
Reply to Office Action of August 13, 2003

46. (Currently amended) The method of claim 44 43, wherein said adenovirus lacking the gene of interest is of the same serotype as said recombinant adenovirus containing the gene of interest.

47. (New) The method according to claim 43, wherein said adenovirus lacking said gene of interest is administered intravenously.

48. (New) The method according to claim 43, wherein said recombinant adenovirus containing the gene of interest is administered intratumorally.

49. (New) The method according to claim 47, wherein said recombinant adenovirus containing the gene of interest is administered intratumorally.